Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PD of Cofrogliptin (HSK7653) in Healthy Volunteers
NCT06003088Phase 1Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cofrogliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Relative Bioavailability (F), Area Under the Curve from time 0 to the last measurable concentration and 4 more. Started Jun 2022; status: completed.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06003088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003088.